title: Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells.
abstract: The estrogen receptors (ERα and ERβ) which are ligand inducible nuclear receptors are recognized as pharmaceutical targets for diseases such as osteoporosis and breast cancer. There is an increasing interest in the discovery of subtype Selective Estrogen Receptor Modulators (SERMs). A series of novel β-lactam compounds with estrogen receptor modulator properties have been synthesized. The antiproliferative effects of these compounds on human MCF-7 breast tumor cells are reported, together with binding affinity for the ERα and ERβ receptors. The most potent compound 15g demonstrated antiproliferative effects on MCF-7 breast tumor cells (IC50=186 nM) and ERα binding (IC50=4.3 nM) with 75-fold ERα/β receptor binding selectivity. The effect of positioning of the characteristic amine containing substituted aryl ring (on C-4 or N-1 of the β-lactam scaffold) on the antiproliferative activity and ER-binding properties of the β-lactam compounds is rationalized in a molecular modeling study.
authors.affiliation: a School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute , Trinity College Dublin , Dublin , Ireland and.
authors.forename: Miriam
authors.initials: M
authors.lastname: Carr
authors.affiliation: a School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute , Trinity College Dublin , Dublin , Ireland and.|b School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute , Trinity College Dublin , Dublin , Ireland.
authors.forename: Andrew J S
authors.initials: AJ
authors.lastname: Knox
authors.affiliation: b School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute , Trinity College Dublin , Dublin , Ireland.
authors.forename: David G
authors.initials: DG
authors.lastname: Lloyd
authors.affiliation: b School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute , Trinity College Dublin , Dublin , Ireland.
authors.forename: Daniela M
authors.initials: DM
authors.lastname: Zisterer
authors.affiliation: a School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute , Trinity College Dublin , Dublin , Ireland and.
authors.forename: Mary J
authors.initials: MJ
authors.lastname: Meegan
mesh_terms: D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D020847:Estrogen Receptor Modulators / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D047628:Estrogen Receptor alpha / Q000037:antagonists & inhibitors*; D047629:Estrogen Receptor beta / Q000037:antagonists & inhibitors; D006801:Humans; D061986:MCF-7 Cells; D008958:Models, Molecular; D015394:Molecular Structure; D013329:Structure-Activity Relationship; D047090:beta-Lactams / Q000138:chemical synthesis / Q000737:chemistry*
chemical_list: D000970:Antineoplastic Agents; D020847:Estrogen Receptor Modulators; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D047090:beta-Lactams
keywords: Antiproliferative activity; azetidin-2-one; breast cancer; estrogen receptor; β-lactam